Interview with Li Xinping, CEO of Mi Duo Bio: The first molecular image CRO "cultivation diary" in China
Recently, Changjiang Securities released an in-depth research report on the CRO industry and gave the CRO relevant listed companies a “optimistic†rating. According to reports, the CRO industry mainly relies on the new drug R&D outsourcing contract for large pharmaceutical companies to achieve profitability, and the service scope basically covers all stages and fields of new drug research and development.
CRO companies are mainly divided into two categories: preclinical and clinical CRO. Specifically, pre-clinical CRO services include chemical synthesis, drug screening, drug modification, commissioned trials, etc. Clinical CRO services include Phase I to IV clinical trial technical services, data management and statistical analysis, registration Declaration, etc.
At present, China's CRO industry is in a period of rapid development. In 2013, the domestic CRO market totaled 22 billion yuan, with a compound annual growth rate of 32.93%, much higher than the international market. In 2015, the total CRO market in China has exceeded 35 billion yuan. According to the report, the investment in pharmaceutical R&D is directly related to the scale of the CRO market. From 2007 to 2012, China's pharmaceutical R&D investment has grown at a compound annual growth rate of 32.8%.
Recently, the author was fortunate enough to interview Li Xinping, CEO of MRO (Nanjing) Biotechnology Co., Ltd., the first molecular imaging CRO company in China. He said that after more than ten years of development, the foreign molecular imaging CRO industry has gradually matured, but the domestic field still In its infancy. PET molecular imaging technology has the outstanding advantages of living imaging, dynamic quantification, self-control, continuous observation, etc., which can greatly shorten the drug development cycle and speed up the marketing of new drugs.
Li Xinping, CEO of Mido (Nanjing) Biotechnology Co., Ltd.
1. Molecular imaging CRO industry "exploiting cattle"
MITRO (Molecular Imaging Translational Research Organization) was established in November 2012. It mainly uses radiolabeling and molecular imaging to study the visualization of drugs in vivo. Drug screening, biodistribution, pharmacokinetic studies, pharmacodynamic evaluation and other new drug development solutions and outsourcing technical services.
In the late 1990s, the world's major pharmaceutical giants (including GSK, Pfizer, Merck, Abbott, Eli Lilly, etc.) set up Translational Imaging, using radioisotope labeling and PET/SPECT molecular imaging technology to speed up the development of new drugs and reduce Risk of failure. The application of such advanced technologies has greatly promoted the development of new drugs in enterprises. However, due to confidentiality requirements, the molecular imaging platforms of each company can only carry out the transformation research of their own projects, and cannot undertake research projects of other pharmaceutical companies. In addition, the operating and maintenance costs of the platform are very high, so the investment income ratio is relatively low.
As the industry's awareness of molecular imaging technology continues to increase, some CRO organizations specializing in radiolabeling and molecular imaging technology have emerged as the times require, and gradually formed a characteristic industry in the CRO industry - molecular imaging CRO. Because of the emergence of professional molecular imaging CRO companies, in order to reduce costs, major pharmaceutical companies began to choose to outsource projects, and even shut down the self-built imaging platform, which greatly promoted the growth and development of the molecular imaging CRO industry. In 2004 and 2006, EMEA and FDA respectively applied molecular imaging technology to drug research to write new drug guidelines.
According to Li Xinping, the predecessor of Mi Duo Bio was Wuxi Jiangyuan Andyco Molecular Nuclear Medicine Research and Development Co., Ltd., which was founded in 2010. The original idea of ​​creating a molecular imaging CRO business in China came from the founding shareholders. Li Xinping and his team became the practitioners of this idea and the “exploiting cattle†of the domestic molecular imaging CRO industry. They spent two and a half years in Wuxi to explore the domestic molecular imaging CRO business model. With the gradual clarity and clarity of the business model, in 2005, Mido (Nanjing) Biotechnology Co., Ltd. was formally established, and Li Xinping was also selected as the “Nanjing 321 Talent Programâ€. After several years of development, Milli has established a total solution and technology outsourcing service system for radiolabeling and molecular imaging new drug development, including international pharmaceutical giants and well-known domestic CRO companies.
Angiography Control Syringes,Angiography,angiography system,angiography machine
Anesthesia Medical Co., Ltd. , https://www.trustfulmedical.com